Answers are grounded in this paper and cite their sources.
Chronic infection by the hepatitis B virus (HBV) has remained a major public health problem. To achieve an HBV cure, we will likely need to combine antivirals with different viral targets as well as immunotherapy. Here, we report data from a pilot proof‐of‐concept clinical trial of nitazoxanide in treating chronic hepatitis B. Conclusion: Nitazoxanide offers novel mechanisms of antiviral activity, and it would be interesting to evaluate the potential of combining nitazoxanide with oral nucleos(t)ide analogues.
No takes yet. Share an insight, caveat, or question.
Rossignol et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: